Biocryst Pharmaceuticals (BCRX) EBIT Margin (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted EBIT Margin of 448.55% for Q1 2026, down 101.22% on a QoQ basis from 36777.54% in Q4 2025, and down 46314.0% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) EBIT Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' EBIT Margin history runs 17 years deep, the most recent figure standing at 448.55% for Q1 2026.
- Quarterly EBIT Margin fell 46314.0% year-over-year to 448.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79.57% (down 8616.0% YoY) and the FY2025 annual result came in at 38.98%, up 3954.0% from the prior year.
- EBIT Margin was 448.55% for Q1 2026 at Biocryst Pharmaceuticals, down from 36777.54% in the prior quarter.
- Across five years, EBIT Margin topped out at 36777.54% in Q4 2025 and bottomed at 448.55% in Q1 2026.
- A 5-year average of 2118.58% and a median of 15.62% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2025 — EBIT Margin soared 3678097 bps — and 2026, when it plunged 46314 bps.
- Biocryst Pharmaceuticals' EBIT Margin stood at 58.22% in 2022, then increased by 22 bps to 45.68% in 2023, then surged by 92 bps to 3.43% in 2024, then soared by 1073192 bps to 36777.54% in 2025, then sank by 101 bps to 448.55% in 2026.
- Business Quant data shows BCRX's EBIT Margin at 448.55% in Q1 2026, 36777.54% in Q4 2025, and 18.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -448.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -448.55% |
| Dec 31, 2025 | 36,777.54% |
| Sep 30, 2025 | 18.56% |
| Jun 30, 2025 | 18.23% |
| Mar 31, 2025 | 14.59% |
| Dec 31, 2024 | -3.43% |
| Sep 30, 2024 | 6.57% |
| Jun 30, 2024 | 8.01% |
| Mar 31, 2024 | -15.62% |
| Dec 31, 2023 | -45.68% |
| Sep 30, 2023 | -13.74% |
| Jun 30, 2023 | -25.10% |
| Mar 31, 2023 | -41.31% |
| Dec 31, 2022 | -58.22% |
| Sep 30, 2022 | -23.01% |
| Jun 30, 2022 | -52.98% |
| Mar 31, 2022 | -100.07% |
| Dec 31, 2021 | -110.64% |
| Sep 30, 2021 | -108.76% |
| Jun 30, 2021 | -59.21% |